http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
-
Relay Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
-
Relay Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
-
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
-
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
-
Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008
-
Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008
-
Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
-
Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
-
Relay Therapeutics (RLAY) Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination
-
Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination
-
Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination
-
Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
-
Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
-
Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Highlights
-
Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Highlights
-
Relay Therapeutics (RLAY) New Interim Clinical Supports RLY-4008 as a Highly Selective FGFR2 Inhibitor
-
Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor
-
Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor
-
Relay Therapeutics (RLAY) Presents Preclinical Data Supportive of RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα
-
Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα
-
Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα
-
Relay Therapeutics to Present Clinical Data on RLY-4008 and Preclinical Data on RLY-2608 at AACR-NCI-EORTC Molecular Targets Conference
-
Relay Therapeutics to Present Clinical Data on RLY-4008 and Preclinical Data on RLY-2608 at AACR-NCI-EORTC Molecular Targets Conference
-
Relay Therapeutics Announces Corporate Updates and Reports Second Quarter 2021 Financial Results
-
Relay Therapeutics Announces Corporate Updates and Reports Second Quarter 2021 Financial Results
-
Relay Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Highlights
-
Relay Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Highlights
-
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
-
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
-
Relay Therapeutics to Participate in Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit
-
Relay Therapeutics to Participate in Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit
-
Relay Therapeutics Reports First Quarter 2021 Financial Results
-
Relay Therapeutics Reports First Quarter 2021 Financial Results
-
Relay Therapeutics Strengthens Computational Leadership Team with Addition of Patrick Riley, Ph.D.
-
Relay Therapeutics Strengthens Computational Leadership Team with Addition of Patrick Riley, Ph.D.
-
Relay Therapeutics to Participate in Fireside Chat at Bank of America 2021 Health Care Conference
-
Relay Therapeutics to Participate in Fireside Chat at Bank of America 2021 Health Care Conference
-
Relay Therapeutics Expands Clinical Leadership Team with Addition of Tara O’Meara and Charles Ferté
-
Relay Therapeutics Expands Clinical Leadership Team with Addition of Tara O’Meara and Charles Ferté
-
Relay Therapeutics (RLAY) announces acquisition of ZebiAI
-
Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI
-
Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI
-
Relay Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
-
Relay Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
-
Relay Therapeutics to Present Preclinical Data on RLY-4008 at AACR Annual Meeting
-
Relay Therapeutics to Present Preclinical Data on RLY-4008 at AACR Annual Meeting
-
Relay Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2021 Oncology Day
-
Relay Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2021 Oncology Day
-
Relay Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

